Ownership and insider activity for Protagonist Therapeutics, Inc. (PTGX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.
Price
| Price | $142.84 |
| Market Cap | $9.2B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.1M | $106.0M | $82.2M | $33.0M | $117.4M | $123.7M | $125.7M | $186.7M | $97.2M | $128.4M |
| Short-term Investments | $56.5M | $38.0M | $46.6M | $100.0M | $188.5M | $203.2M | $111.6M | $154.9M | $321.7M | $439.0M |
| Receivables | $2.2M | $1.8M | $4.6M | $6.8M | $3.8M | $5.3M | $52000 | $10.3M | $168.5M | $4.5M |
| Inventory | -$7.7M | -$8.7M | $2.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $83.2M | $150.9M | $137.5M | $145.3M | $315.6M | $340.7M | $243.1M | $355.6M | $591.6M | $577.6M |
| Property, Plant & Equipment | $562000 | $879000 | $861000 | $7.7M | $6.4M | $6.7M | $4.6M | $2.1M | $12.6M | $11.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $94.0M | $163.7M | $139.5M | $154.9M | $324.5M | $347.7M | $247.9M | $358.0M | $744.7M | $669.9M |
| Accounts Payable | $1.2M | $1.3M | $5.7M | $2.8M | $3.1M | $1.6M | $3.6M | $772000 | $1.6M | $5.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $510000 | $2.3M |
| Total Current Liabilities | $6.4M | $42.6M | $26.2M | $35.4M | $40.2M | $44.0M | $31.2M | $21.3M | $47.4M | $45.4M |
| Long-term Debt | 0 | 0 | 0 | $9.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $6.4M | $43.1M | $27.0M | $75.0M | $44.9M | $47.7M | $32.3M | $21.3M | $69.4M | $55.2M |
| Retained Earnings | -$64.6M | -$101.5M | -$140.5M | -$217.7M | -$283.8M | -$409.4M | -$536.8M | -$615.7M | -$340.5M | -$470.7M |
| Total Equity | -$64.6M | -$101.5M | -$140.5M | $80.0M | $279.6M | $300.0M | $215.6M | $336.7M | $675.3M | $614.7M |
| Total Debt | 0 | 0 | 0 | $17.0M | $6.0M | $5.9M | $3.7M | $1.1M | $10.9M | $10.3M |
| Net Debt | -$77.6M | -$144.0M | -$128.9M | -$116.0M | -$299.9M | -$321.0M | -$233.7M | -$340.5M | -$408.0M | -$557.0M |
| Working Capital | $76.8M | $108.4M | $111.3M | $109.9M | $275.4M | $296.7M | $211.9M | $334.3M | $544.2M | $532.1M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 12.71 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 59.63 |
Profitability
| Return on Equity | -21.17% |
| Return on Invested Capital | -25.23% |
| Return on Assets | -19.43% |
| Gross Margin | 97.34% |
| Operating Margin | -343.63% |
| Net Margin | -282.83% |
Related companies: ACLX · AKRO · ALKS · CRNX · IMVT · KYMR · NAMS
Explore sector: Healthcare · Biotechnology
More sections of PTGX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks